Phase 3 trial of milvexian for ACS prevention completes enrollment

The LIBERATE trial is a Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of milvexian in participants after a recent acute coronary syndrome (ACS). The study's primary objective is to determine if milvexian, in addition to standard-of-care, is superior to placebo in reducing the risk of a major adverse cardiovascular event (MACE). The primary outcome measure is the time to the first occurrence of MACE, which is a composite of cardiovascular death, myocardial infarction, and ischemic stroke. The study enrolled 14,194 participants and has a follow-up duration of 34.0 months. The study sponsor is Janssen Research & Development, LLC. The study start date was April 7, 2023, and the primary completion date is February 6, 2026. The study status is listed as COMPLETED, which in this context refers to the completion of the enrollment and follow-up phases as per the provided timeline. The abstract does not report any efficacy results, safety data, or statistical outcomes such as hazard ratios, p-values, or confidence intervals. Therefore, no conclusions regarding the superiority or non-inferiority of milvexian compared to placebo can be drawn from the provided abstract information. The summary is limited to the design, population, and planned outcomes as explicitly stated in the abstract.

If you've just had a serious heart event like a heart attack, your biggest fear is probably having another one. Doctors call this cluster of events 'acute coronary syndrome.' After the initial scare, the focus shifts to preventing the next one—a heart attack, a stroke, or worse. A major study involving over 14,000 people recently wrapped up, testing a potential new layer of defense. The study looked at a drug called milvexian. Researchers wanted to know if adding milvexian to the standard medications and care people already receive would work better than that standard care plus a placebo (a dummy pill). The main thing they were watching for was whether milvexian could reduce the combined risk of three major problems: death from heart or blood vessel causes, a heart attack, or an ischemic stroke (a stroke caused by a blocked blood vessel in the brain). They tracked people for the time it took for the first of these events to happen. The study was designed to see if milvexian was superior, or better, at lowering this risk. The results of this large trial will help determine if this drug could become a new option for protecting hearts after a major scare.